Capivasertib
Approved · FDA / EMAAlso known as Truqap, Capivasertibum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Molecular Analysis for Therapy Choice (MATCH)
Indication expansion: CAPIVASERTIB (NDA218197)
Label change: CAPIVASERTIB (NDA218197)
Label change: CAPIVASERTIB (NDA218197)
Label change: CAPIVASERTIB (NDA218197)
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast… Show full indicationShow less
Truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, Truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practice standards should be considered.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes6
Journals, researchers & institutions
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology2
- The Annals of pharmacotherapy1
- The Lancet. Oncology1
- The New England journal of medicine1
- Turner NC3
- Abraham J2
- Baird RD2
- Cortes J2
- de Bruin EC2
- Foxley A2
- Park YH2
- Bliss JM1
- Cancer Research UK Cambridge Centre2
- American Society of Clinical Oncology1
- Barts Cancer Institute1
- Barts Hospital NHS Trust1
- Breast Cancer Now Toby Robins Research Centre1
- Cancer Research UK Edinburgh Centre1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 4 of the same disease areas as Capivasertib in the shared literature.
Studied across 4 of the same disease areas as Capivasertib in the shared literature.
Studied across the same disease area as Capivasertib in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.